<DOC>
	<DOCNO>NCT00456716</DOCNO>
	<brief_summary>Open label study sorafenib</brief_summary>
	<brief_title>Sorafenib BAC Never-Smokers With Lung Adenocarcinoma</brief_title>
	<detailed_description>Open label study use oral sorafenib 800 mg daily stage III-IV BAC lung cancer Stage III-IV adenocarcinoma lung nonsmoker ( less &lt; 100 cigarette lifetime ) .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Age &gt; 18 Life expectancy &gt; 12 week Biopsyproven BAC adenocarcinoma Willing provide smoke status Selected IIIB stage IV cancer incompletely resect unresectable O2 saturation &lt; 88 % room air Pregnant nursing woman Surgery radiation therapy within 4 week start study Major heart condition within 6 month start therapy Certain concomitant medication prohibit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>BAC lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>